Jade Biosciences is focused on developing innovative, best-in-class therapies to address critical unmet needs in autoimmune diseases. The company's lead candidate, JADE101, is being developed for the treatment of immunoglobulin A nephropathy (IgAN), with a Phase 1 study ongoing and a pipeline including JADE201 and JADE-003.
